Effects of tofacitinib on lymphocytes in rheumatoid arthritis: Relation to efficacy and infectious adverse events

Rheumatology (United Kingdom)

Volumn 53, Issue 5, 2014, Pages 914-918

  Sonomoto, Koshiro ^a   Yamaoka, Kunihiro ^a   Kubo, Satoshi ^a   Hirata, Shintaro ^a   Fukuyo, Shunsuke ^a   Maeshima, Keisuke ^b   Suzuki, Katsunori ^a   Saito, Kazuyoshi ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b OITA UNIVERSITY   (Japan)

Author keywords

Janus kinase inhibitor; Rheumatoid arthritis; T lymphocytes; Tofacitinib

Indexed keywords

JANUS KINASE INHIBITOR; RHEUMATOID ARTHRITIS; T LYMPHOCYTES; TOFACITINIB;

ADULT; AGED; ARTHRITIS, RHEUMATOID; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; CELL PROLIFERATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFECTION; MALE; MIDDLE AGED; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84898825550     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket466     Document Type: Article

References (13)

1. Russell SM, Tayebi N, Nakajima H et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995;270:797-800.
2. Changelian PS, Flanagan ME, Ball DJ et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003;302:875-8.
3. van Vollenhoven RF, Fleischmann R, Cohen S et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19.
4. Meyer DM, Jesson MI, Li X et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm 2010;7:41.
5. Maeshima K, Yamaoka K, Kubo S et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon- gamma and interleukin-17 production by human CD4+ T cells. Arthritis Rheum 2012;64:1790-8.
6. Rosengren S, Corr M, Firestein GS et al. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis 2012;71:440-7.
7. Sandborn WJ, Ghosh S, Panes J et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012;367:616-24.
8. Vincenti F, Tedesco Silva H, Busque S et al. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant 2012;12:2446-56.
9. Conklyn M, Andresen C, Changelian P et al. The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing. J Leukoc Biol 2004;76:1248-55.
10. Paniagua R, Si MS, Flores MG et al. Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts. Transplantation 2005;80:1283-92.
11. Cohen S, Radominski SC, Asavatanabodee P et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor: analysis of infections and all-cause mortality across phase 3 and long-term extension studies in patients with rheumatoid arthritis. Arthritis Rheum 2011;63(Suppl 10):S153.
12. Scotet E, Peyrat MA, Saulquin X et al. Frequent enrichment for CD8 T cells reactive against common herpes viruses in chronic inflammatory lesions: towards a reassessment of the physiopathological significance of T cell clonal expansions found in autoimmune inflammatory processes. Eur J Immunol 1999;29:973-85.
13. Takada K, Jameson SC. Naive T cell homeostasis: from awareness of space to a sense of place. Nat Rev Immunol 2009;9:823-32.